Biopharmaceutical company Dyax has dosed the first subject in a Phase I study of fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, leveraging the company’s phage display technology platform.
The study will assess the safety and tolerability of single administration of DX-2930, developed by the company as a subcutaneous injection for the prevention of hereditary angioedema (HAE) attacks.
Dyax executive vice president and chief medical officer Dr Burt Adelman said that there is a significant requirement for an effective, safe and well tolerated prophylactic agent to treat HAE.
"DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein," Adelman added.
"We look forward to completing this study and moving forward rapidly with this important clinical program."
The single-centre, randomised, double-blind, placebo-controlled study will assess the safety and tolerability of DX-2930 as well as characterise the pharmacokinetics (PK) of single, subcutaneous administrations of the investigational candidate in healthy subjects.
The study conducted at the clinical trials unit of Vince & Associates Clinical Research will enrol approximately 32 subjects into four ascending dose cohorts (n=8 per cohort) of DX-2930 or placebo.
Dyax president and CEO Gustav Christensen said, "We believe our knowledge of the plasma kallikrein pathway provides us with unique insight and a significant advantage in developing and commercialising this product candidate."